Cannabis Psilocybin and cannabis improve breast cancer treatment efficacy: Grace Health New study also suggests that plant-derived medicines can reduce inflammation and improve mental health Rowan DunneSeptember 30, 2022
M&A Irwin Naturals acquires Ketamine Media platform 'The total consideration is to be paid in a combination of cash and stock' says Irwin Rowan DunneSeptember 29, 2022
Psychedelics Psyence sends psilocybin mushrooms to Psilo Pharma in Portugal Shipment marks company's first successful export to Europe and second to date Rowan DunneSeptember 29, 2022
Canada Cybin acquires license for psychedelic molecules from Mindset Cybin will pay Mindset an initial US$500K and 'development milestone payments' that could potentially total US$9.5M afterward Rowan DunneSeptember 27, 2022
Canada PsyCan pushes federal policy-makers to lift restrictions on psychedelics Non-profit says Canada needs to make room for healthcare innovation with respect to psychedelic therapies Rowan DunneSeptember 21, 2022
Canada Numinus launches ketamine-assisted therapy in Toronto Neurology Centre of Toronto in Forest Hill expands its therapy catalogue Rowan DunneSeptember 21, 2022
Psychedelics MindMed doses first patient with MDMA-like compounds in new trial New study will compare the effects of MDA and MDMA in humans for the first time Rowan DunneSeptember 20, 2022
Canada ATMA receives Health Canada approval for new psilocybin trial Study will evaluate psilocybin efficacy in healthcare workers with mental health challenges related to pandemic Rowan DunneSeptember 15, 2022
Stock News MindMed re-establishes Nasdaq listing requirements News follows a 1-for-15 reverse share split by the company at the end of August and ensuing loss of stock value Rowan DunneSeptember 14, 2022
Cannabis Delix gets recognized as leading start-up by Nature Biotechnology Renowned academic journal praises company for development of psychoplastogens Rowan DunneSeptember 14, 2022